Save an EXTRA 10% OFF your order with code SAVE10
Home / Learn / Kratom Legal Status 2026: Bans, KCPA States & the Complete FDA Timeline

Kratom Legal Status 2026: Bans, KCPA States & the Complete FDA Timeline

Updated June 12, 2026

Key Takeaway

As of April 2026, kratom is legal under U.S. federal law but banned in seven states (Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, Wisconsin). Rhode Island reversed its ban effective April 1, 2026. Eighteen-plus states have adopted the Kratom Consumer Protection Act (KCPA), which regulates rather than prohibits kratom by requiring 21+ age verification, lab-tested products, and accurate labeling. Always check local law before traveling with kratom — state-level enforcement varies dramatically.

The kratom legal status in the United States is a patchwork of state laws, federal agency actions, and international reviews that has evolved dramatically over the past decade. As of 2026, kratom remains legal at the federal level but is banned in seven states, regulated under the Kratom Consumer Protection Act in over a dozen others, and exists in a legal gray area in cities and counties that have imposed their own restrictions.

This article provides the definitive guide to the kratom ban landscape, the complete FDA and DEA timeline, the growing KCPA movement, and what the future holds for kratom consumers across the country. Whether you’re checking is kratom legal in your state or trying to understand the federal regulatory history, this is the comprehensive resource you need.

Kratom occupies a unique position in American drug policy. The Drug Enforcement Administration (DEA) has not classified it as a controlled substance at the federal level, meaning it is legal under federal law. However, individual states retain the authority to regulate or ban substances within their borders, and seven states have done so.

The broader trend since 2019 has moved decisively toward regulation over prohibition. More than two dozen states and the District of Columbia now have some form of kratom regulation in place. The Kratom Consumer Protection Act—model legislation developed by the American Kratom Association (AKA)—has been the primary vehicle for this regulatory approach, establishing product safety standards, age restrictions, and labeling requirements rather than outright bans.

Rhode Island made history in 2025 by becoming the first state to reverse a kratom ban, signing the Rhode Island Kratom Act and establishing a regulated market effective April 1, 2026. Meanwhile, Louisiana moved in the opposite direction, enacting one of the most severe bans in the country in August 2025.

Which states have banned kratom?

As of March 2026, seven states maintain complete bans on kratom possession, sale, and distribution.[10] These bans classify kratom’s primary alkaloids—mitragynine and 7-hydroxymitragynine—as controlled substances.

State Year Banned Classification Key Details
Indiana 2014 Synthetic drug One of the first states to ban; classifies kratom alkaloids as synthetic substances
Wisconsin 2014 Schedule I Banned alongside Indiana as an early prohibitor; classifies mitragynine as Schedule I
Alabama 2016 Schedule I Targets mitragynine and 7-hydroxymitragynine specifically as controlled substances
Arkansas 2016 Schedule I Classified under state controlled substances list; strong opposition from health officials
Vermont 2016 Regulated drug Implemented through Board of Health administrative action rather than legislation
Louisiana 2025 Schedule I SB 154 effective Aug 1, 2025; places kratom in same category as heroin and LSD; up to 5 years for possession
Connecticut 2026 Schedule I HB 6855 signed March 2026; Schedule I classification; announced by Lt. Gov Bysiewicz and AG Tong

Rhode Island was previously on this list, having banned kratom in 2017. However, the state signed the Rhode Island Kratom Act in July 2025, reversing the ban and establishing a regulated framework effective April 1, 2026. This was the first successful reversal of a state-level kratom ban in U.S. history.

Local and Municipal Bans

Even in states where kratom is legal, certain cities and counties have enacted their own prohibitions. Consumers should verify local laws before purchasing or traveling with kratom products:

  • San Diego, Oceanside, and Newport Beach, California — Local bans on kratom sales. Additionally, California CDPH launched a statewide enforcement campaign in March 2026 removing kratom products from retail shelves. See our California kratom guide for full details. Kratom is legal at the state level in California
  • Sarasota County, Florida — Local ban despite kratom being legal throughout Florida
  • Jerseyville, Illinois — Municipal prohibition
  • Denver, Colorado — Banned for human consumption, though legal elsewhere in Colorado
  • Union County, Mississippi — Local restriction

Which states have adopted the Kratom Consumer Protection Act?

The Kratom Consumer Protection Act represents the most significant legislative success for kratom advocacy. Developed as model legislation by the American Kratom Association, the KCPA provides a framework that protects consumers while addressing legitimate safety concerns through regulation rather than prohibition.

State Year Enacted Notable Provisions
Utah 2019 First state to pass KCPA; established the model framework
Arizona 2019 Age restriction 18+; labeling requirements
Georgia 2019 Age restriction 18+; product registration
Nevada 2019 Labeling and purity standards
Oklahoma 2020 Age restriction 18+; bans adulterated products
Colorado 2020 Statewide regulation; note: Denver maintains local ban for human consumption
Oregon 2021 Comprehensive labeling and testing requirements
Virginia 2021 Age restriction; product purity standards
Mississippi 2022 Statewide framework with age restrictions
West Virginia 2022 Product safety and labeling standards
Missouri 2022 Age 21+ purchase restriction
Kansas 2023 Consumer protection and labeling
Tennessee 2023 Product quality and age restrictions
Kentucky 2023 Comprehensive product standards
North Dakota 2023 Age and labeling requirements
South Carolina 2024 Product regulation framework
Maine 2024 Consumer safety standards
Rhode Island 2025 (effective April 2026) First state to reverse a ban; establishes regulated market with tax framework

Additional states including Texas, New York, Ohio, and Florida allow kratom sales without KCPA-specific legislation, though some have age restrictions or other regulations in place.

What is the complete FDA and DEA kratom timeline?

Understanding today’s kratom legal status requires understanding the decade-long regulatory battle between federal agencies, scientists, advocates, and Congress. The following timeline documents every major event in the federal kratom regulatory story.

Date Event Significance
2012 FDA issues Import Alert 54-15 First federal action; authorized detention of kratom shipments at the border without examination
2014 Indiana and Wisconsin enact bans First state-level prohibitions; classified kratom alkaloids as synthetic substances
Feb 2014 FDA issues second Import Alert Expanded border seizure authority for kratom products
2016 Alabama, Arkansas, and Vermont ban kratom Three additional states enact prohibitions; Vermont acts through Board of Health
Aug 30, 2016 DEA announces emergency scheduling Published Federal Register notice (Docket No. DEA-442) to place mitragynine and 7-hydroxymitragynine in Schedule I
Sep 26, 2016 Hogan Lovells files formal objection on behalf of AKA Legal brief argues DEA’s use of emergency scheduling for a natural botanical is “completely unprecedented”
Sep 2016 51 members of Congress sign bipartisan letter to DEA Senators and Representatives urge DEA to withdraw scheduling notice and open public comment period
Oct 12, 2016 DEA withdraws emergency scheduling notice First time DEA reversed an emergency scheduling action; opened unprecedented public comment period
Nov 2016 Pinney Associates publishes 8-Factor Analysis Independent scientific review concludes kratom does not meet Schedule I criteria; recommends no scheduling
Dec 2016 DEA receives 142,000+ public comments Largest public comment response in DEA history; overwhelming opposition to scheduling
Nov 2017 FDA Commissioner Gottlieb issues public health advisory FDA claims kratom is an traditional substance based on computational modeling; recommends scheduling to DEA
Feb 2018 FDA links kratom to 44 deaths FDA expands death count; later analysis reveals nearly all cases involved other substances or pre-existing conditions
Mar 2018 AKA publishes rebuttal of FDA death data (Jane Babin, Ph.D., Esq.) Detailed analysis shows FDA’s death claims fail evidentiary standards; only one case involved kratom alone
Jun 2018 Nine leading scientists write to Congressional leadership Letter urges Congress to prevent scheduling; warns banning kratom would drive traditional substance users back to dangerous drugs
Nov 2018 FDA’s 8-Factor Analysis leaked via FOIA HHS had recommended Schedule I; scientists publish detailed critique identifying significant errors
2019 First KCPA states: Utah, Arizona, Georgia, Nevada States begin choosing regulation over prohibition; establishes KCPA as viable model
Oct 2021 WHO Expert Committee reviews kratom ECDD recommends against international scheduling; finds insufficient evidence of public health risk
2022–2024 KCPA expansion wave Multiple states enact consumer protection legislation; total reaches 18+ states
Jul 2025 Rhode Island reverses kratom ban First-ever ban reversal; signs KCPA effective April 1, 2026
Aug 2025 Louisiana SB 154 takes effect Classifies kratom as Schedule I; up to 5 years for possession; driven by concerns over enhanced products

What happened with the 2016 DEA emergency scheduling attempt?

The most pivotal moment in kratom’s regulatory history came on August 30, 2016, when the DEA published a Federal Register notice announcing its intent to temporarily place mitragynine and 7-hydroxymitragynine—kratom’s two primary alkaloids—into Schedule I of the Controlled Substances Act (DEA Docket No. DEA-442). [1]

The notice cited kratom as posing “an imminent hazard to public safety,” invoking emergency scheduling authority under 21 U.S.C. § 811(h). As legal experts at Hogan Lovells noted in their formal objection on behalf of the AKA, this use of emergency scheduling was “completely unprecedented” for a natural botanical product with decades of documented safe use. [2] The emergency scheduling provision was designed for novel synthetic “designer” substances that emerge rapidly on illicit markets—not for a well-known plant in the coffee family (Hogan Lovells, 2016).

The proposed scheduling would have criminalized possession of kratom overnight, affecting an estimated 3–5 million American consumers at the time. The legal consequences would have been identical to possessing heroin or LSD.

How did scientists and Congress push back against DEA scheduling?

The response to the DEA’s scheduling attempt was unlike anything the agency had experienced. Within weeks, a powerful coalition of scientists, lawmakers, consumer advocates, and everyday Americans mobilized in opposition.[11]

Congressional Opposition

In September 2016, a bipartisan group of 51 members of Congress—including both senators and representatives—signed a letter to then-Acting DEA Administrator Chuck Rosenberg urging the agency to withdraw its emergency scheduling notice. [3] The letter called for a public comment period and proper scientific review before any scheduling action, arguing that the DEA had failed to follow standard procedures (U.S. Senate Letter to DEA, 2016).

The Scientific Community Responds

Pinney Associates, an independent scientific consulting firm, published a comprehensive 8-Factor Analysis in November 2016 [4] evaluating kratom under the same criteria the Controlled Substances Act requires for scheduling decisions. Their 127-page analysis concluded that kratom did not meet the criteria for Schedule I placement: its abuse potential was low, its pharmacological profile differed significantly from classical traditional substances, and existing evidence did not support a finding of imminent public safety hazard (Pinney Associates, 2016).

In June 2018, nine of the nation’s leading kratom researchers wrote directly to Congressional leadership [7]—including Majority Leader McConnell, Speaker Ryan, Minority Leader Pelosi, and Minority Leader Schumer. Their letter stated unequivocally: “Based on the substantial science and safety signal data, we conclude that kratom does not meet the statutorily mandated criteria for Schedule I substances.” The scientists warned that banning kratom would have a “foreseeable negative public health consequence” by driving thousands of former traditional substance users back to dangerous drugs (Kratom Scientist Letter to Congressional Leaders, 2018).

Unprecedented Public Response

The DEA’s reversal on October 12, 2016, was itself unprecedented—the first time the agency had ever withdrawn an emergency scheduling notice. The subsequent public comment period generated over 142,000 comments, the largest in DEA history, with the overwhelming majority opposing scheduling.

Challenging the FDA’s Evidence

When the FDA’s Commissioner Scott Gottlieb issued a public health advisory in November 2017 claiming kratom was an “traditional substance” and linking it to 44 deaths, the scientific and advocacy community responded with detailed rebuttals. Dr. Jane Babin’s analysis for the AKA found that the FDA’s death data was fundamentally flawed [5]: “the overwhelming majority of the cited deaths fails to provide a cohesive or reasonable scientific basis to conclude any of the deaths was caused by kratom.” Nearly all cases involved polysubstance use or pre-existing wellness conditions (Babin, 2018).

When the FDA’s own 8-Factor Analysis recommending Schedule I placement was leaked through a FOIA request in November 2018, scientists published a comprehensive critique identifying significant methodological errors, selective data presentation, and conclusions unsupported by the evidence presented [6] (Scientists’ Response to FDA’s 8-Factor Analysis, 2018).

What did the WHO decide about kratom in 2021?

In October 2021, the World Health Organization’s Expert Committee on Drug Dependence (ECDD) completed a critical review of kratom (Mitragyna speciosa) during its 44th meeting. After evaluating the available scientific evidence, the ECDD recommended against placing kratom under international control. [8][9]

The WHO’s pre-review report acknowledged kratom’s pharmacological activity at alkaloid receptors but noted the significant differences between kratom and classical traditional substances, particularly regarding respiratory low mood risk. The committee found insufficient evidence to conclude that kratom posed a significant risk to public health at the international level (WHO ECDD, 2021).

This decision was a landmark moment for kratom advocacy. An unfavorable WHO recommendation could have triggered international scheduling under the Single Convention on Narcotic Drugs, potentially forcing all member nations—including the United States—to ban kratom. The favorable outcome removed that threat and provided a powerful reference point for domestic policy debates.

What is the current federal status of kratom?

As of 2026, kratom’s federal status remains unchanged: it is not a controlled substance under the Controlled Substances Act. The DEA has not moved forward with scheduling since withdrawing its 2016 emergency notice, and the FDA’s 2017 scheduling recommendation to the DEA has not resulted in further action.[12]

The FDA continues to maintain its position that kratom has “no approved wellness uses” and periodically issues consumer advisories. The agency has used its authority to seize kratom products at the border under Import Alert 54-15, and has issued warning letters to companies making unapproved therapeutic claims about kratom products.

However, several developments suggest the federal regulatory posture has softened:

  • The WHO’s 2021 decision not to recommend international scheduling removed significant pressure for domestic action
  • The growing number of states with KCPA legislation demonstrates a viable regulatory alternative to prohibition
  • No new federal scheduling actions have been initiated since 2017
  • The National Institute on Drug Abuse (NIDA) has funded research into kratom’s therapeutic potential, particularly for traditional substance use disorder

What does the Kratom Consumer Protection Act actually do?

The Kratom Consumer Protection Act addresses the legitimate concerns that drive kratom ban efforts—product safety, adulteration, and youth access—without criminalizing adult consumers. Core provisions of the KCPA framework include:

  • Age restrictions: Prohibits sale to individuals under 18 or 21 (varies by state)
  • Product labeling: Requires clear labeling of ingredients, alkaloid content, and manufacturer information
  • Adulteration ban: Prohibits the sale of kratom products contaminated with dangerous substances or containing synthetic alkaloids
  • 7-OH limits: Some states limit concentrations of 7-hydroxymitragynine to naturally occurring levels, addressing the enhanced product concerns that drove Louisiana’s ban
  • Lab testing: Requires third-party testing for contaminants, heavy metals, and alkaloid content
  • Penalties for violations: Establishes civil and criminal penalties for selling adulterated or mislabeled products

The KCPA model directly addresses the enhanced product problem. Many recent regulatory concerns stem from products containing unnaturally high concentrations of 7-hydroxymitragynine, which at elevated levels “acts like a powerful traditional substance, which can increase the risk of addiction, overdose, and other serious health effects.” The KCPA framework distinguishes between traditional kratom products with natural alkaloid profiles and potentially dangerous enhanced formulations.

At Amazing Botanicals, all of our lab-tested kratom products meet the highest quality standards. We follow AKA GMP-certified manufacturing processes, and our third-party lab results are available for every batch. We sell only traditional kratom powder and kratom capsules with natural alkaloid profiles—never enhanced or synthetic formulations.

How do I check kratom legality in my state?

Click any state for the full legal guide. Hover for a quick status summary.

🟢 Legal | 🟢 KCPA Regulated | 🟡 Threatened/Complicated | 🔴 Banned — Hover for details, click for full guide

What are the active 2026 threats to kratom legality?

2026 has become one of the most turbulent years for kratom legislation. Several states have active ban bills, and a new federal threat has emerged:

Federal Threat: Senator Ricketts’ Letter to FDA

In March 2026, a group of U.S. Senators led by Senator Pete Ricketts sent a letter to the FDA urging action to schedule kratom federally. This represents the most significant federal-level threat since the 2016 DEA scheduling attempt. The American Kratom Association is mobilizing consumer advocacy at americanadvocacy.org.

States with Active Ban Bills (2026)

State Bill Status Details
Michigan HB 5537 ⚠️ Passed House Passed House March 18, 2026; now in Senate. Would ban production and sale.
Kansas SB 497 / HB 2365 ⚠️ Passed Senate 33-5 Senate voted 33-5 for Schedule I; also snuck into HB 2365 via Conference Committee.
Tennessee HB 1649 ⚠️ Passed Committee “Matthew’s Law” — passed Judiciary Committee after emotional family testimony.
Illinois HB 4930 Introduced Would ban sales; competing KCPA bills HB 5242 and HB 4737 also introduced.
Maryland HB 1523 / SB 820 Hearing held Cross-filed restrictive bills; would take effect July 1, 2026 if passed.

California CDPH Enforcement Campaign

In March 2026, Governor Newsom announced that the California Department of Public Health (CDPH) achieved a 95% compliance rate for the removal of kratom products from retail businesses. Over 3,308 kratom and 7-OH products were removed from shelves. While not a legislative ban, this represents the most aggressive state enforcement action against kratom retail sales in the country. See our complete California kratom guide.

Defeated Ban Attempts (2026)

  • Wyoming — HB 185 (ban) was defeated
  • South Dakota — Ban attempt failed
  • Arizona — Attempt to classify kratom as a narcotic failed in committee

What is the state-by-state kratom outlook for 2026 and beyond?

The kratom regulatory landscape continues to evolve rapidly. Here’s what to watch in key states:

States Where Bans May Be Reversed

Rhode Island’s successful ban reversal has energized advocacy efforts in other prohibited states. Arkansas and Vermont are the most likely candidates for reconsideration, with active AKA advocacy campaigns underway. Indiana and Wisconsin’s early bans face strong institutional inertia, but Rhode Island’s precedent demonstrates that reversal is possible.

States Considering KCPA Legislation

Several states without existing kratom-specific legislation are considering KCPA bills, including New York, Ohio, and others. As the number of KCPA states grows, pressure increases on remaining states to adopt regulatory frameworks.

Enhanced Product Regulation

Louisiana’s ban was driven primarily by concerns over enhanced kratom products containing concentrated 7-hydroxymitragynine. This issue is likely to drive additional regulation in states that currently have minimal oversight. The KCPA’s provisions addressing adulteration and synthetic alkaloids provide a proven alternative to the blunt instrument of total prohibition.

What practical guidance should kratom consumers follow?

Given the complex and evolving kratom legal status across the country, consumers should take these precautions:

  • Verify your local laws: Check both state and local regulations. Visit our kratom legality hub for state-specific information
  • Never transport kratom into banned jurisdictions: Possession in a banned state can result in criminal charges regardless of where you purchased the product
  • Plan travel routes carefully: Avoid driving through banned states with kratom in your vehicle
  • Choose reputable vendors: Purchase from companies that provide third-party lab testing, follow GMP standards, and sell products with natural alkaloid profiles
  • Avoid enhanced products: Products with unnaturally high 7-hydroxymitragynine concentrations face increasing regulatory scrutiny and may be driving new ban efforts
  • Stay informed: Kratom laws change frequently. Follow the American Kratom Association for legislative updates

Learn more about kratom at our education center, or explore our complete selection of premium kratom products.

Frequently Asked Questions

Is kratom legal in the United States?

Kratom is legal at the federal level but banned in seven states: Alabama, Arkansas, Indiana, Louisiana, Vermont, and Wisconsin. Rhode Island reversed its ban effective April 1, 2026. Over a dozen states regulate kratom through the Kratom Consumer Protection Act. Check our state-by-state guide for the most current information.

Which states have banned kratom?

As of 2026, kratom is banned in Alabama (2016), Arkansas (2016), Connecticut (2026), Indiana (2014), Louisiana (2025), Vermont (2016), and Wisconsin (2014). Rhode Island’s ban was reversed in 2025.

What is the Kratom Consumer Protection Act (KCPA)?

The KCPA is model legislation that regulates kratom by requiring age verification, product labeling, lab testing, and banning adulterated or synthetic products. It has been enacted in 18+ states and represents the primary alternative to prohibition.

Did the DEA try to ban kratom?

Yes. In August 2016, the DEA announced plans to emergency schedule kratom’s alkaloids as Schedule I substances. After unprecedented public opposition—142,000+ comments, 140,000+ petition signatures, and letters from 51 members of Congress—the DEA withdrew its notice in October 2016, the first such reversal in agency history.

What did the WHO say about kratom?

In October 2021, the WHO Expert Committee on Drug Dependence reviewed kratom and recommended against international scheduling, finding insufficient evidence of public health risk to warrant international control.

Can I travel with kratom across state lines?

You should never transport kratom into banned states. Possession in Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, or Wisconsin can result in criminal charges. Also check for local bans in cities like San Diego (CA) and Sarasota County (FL).

Is kratom an traditional substance?

Kratom is not classified as an traditional substance. It is a botanical from the coffee family (Rubiaceae) whose alkaloids interact with alkaloid receptors as partial agonists. Scientists have noted its pharmacology differs significantly from classical traditional substances, with a lower risk profile for respiratory low mood.

Why did Louisiana ban kratom in 2025?

Louisiana’s SB 154 was driven by concerns over adulterated and enhanced kratom products containing unnaturally high concentrations of 7-hydroxymitragynine. The law classifies kratom as Schedule I with penalties up to 5 years for possession.

Has the FDA approved kratom for any wellness use?

No. The FDA has not approved kratom for any wellness use. However, the agency’s 2017 scheduling recommendation was challenged by scientists who identified significant errors in the FDA’s 8-factor analysis, and no scheduling has resulted.

What happens if I’m caught with kratom in a banned state?

Penalties vary. Louisiana carries up to 5 years imprisonment. Alabama and Arkansas manage kratom as a Schedule I substance. Indiana and Wisconsin classify kratom alkaloids as synthetic substances with corresponding criminal penalties.

References

  1. Drug Enforcement Administration. “Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine Into Schedule I.” Federal Register, Vol. 81, Docket No. DEA-442, August 31, 2016.
  2. Hogan Lovells US LLP. “Letter to Acting Administrator Chuck Rosenberg Re: Docket No. DEA-442, Emergency Scheduling of Mitragynine and 7-Hydroxymitragynine.” September 26, 2016.
  3. U.S. Senate. Bipartisan Letter to DEA Regarding Kratom Scheduling. September 2016.
  4. Pinney Associates. “Assessment of Kratom under the CSA Eight Factors and Scheduling Recommendation.” November 28, 2016.
  5. Babin, J. “The FDA Kratom Death Data: Exaggerated Claims, Discredited Research, and Distorted Data Fail to Meet the Evidentiary Standard for Placing Kratom as a Schedule I Controlled Substance.” American Kratom Association Policy Report, Vol. 1, March 2018.
  6. Henningfield, J.E., et al. “Comment on FDA Kratom CSA 8-Factor Analysis.” Letter to HHS, DEA, FDA, and NIDA. November 28, 2018.
  7. Hemby, S.E., et al. Letter to Congressional Leadership Regarding FDA Scheduling Recommendation for Kratom. June 21, 2018.
  8. World Health Organization Expert Committee on Drug Dependence (ECDD). “Pre-Review Report: Kratom (Mitragyna speciosa).” 44th ECDD Meeting, October 11–15, 2021.
  9. World Health Organization. “Summary of Assessments, Findings and Recommendations of the 44th WHO Expert Committee on Drug Dependence.” 2021.
  10. Legislative Analysis and Public Policy Association. “Regulation of Kratom in America.” 2019.
  11. Garcia-Romeu, A., et al. “Kratom Policy: The Challenge of Balancing Therapeutic Potential with Public Safety.” Drug and Alcohol Dependence, 2019.
  12. Pinney Associates. “8-Factor Analysis Update.” 2021.

Brian Kan — Founder, Amazing Botanicals
About the Author
Brian Kan
Founder, Amazing Botanicals — 10+ Years in the Kratom Industry

Brian has built Amazing Botanicals from the ground up over the past decade, overseeing sourcing, independent lab testing, and quality control across 132 products and more than 220,000 customer orders. He holds AKA GMP qualification and writes on kratom science, safety, and responsible use.

← Back to Learning Center

Shop Lab-Tested Kratom

Browse our full selection of AKA GMP-qualified kratom — powder, capsules, extracts, and more. Free shipping on orders $99+.


Shop All Kratom
Disclaimer: This content is for educational purposes only and is not intended as medical, legal, or professional advice. Kratom is not approved by the FDA to diagnose, treat, cure, or prevent any disease.
Your Cart (0)

Your cart is empty

Browse Products